Lung Diseases Clinical Trial
Official title:
Prevalence of Sleep Apnea in Women
To identify the prevalence of sleep apnea (SA) in women and its relationship to age; to predict those women at risk for sleep apnea; and to define the natural history of those with sleep apnea.
BACKGROUND:
Often sleep apnea is accompanied by considerable morbidity; the associated excessive daytime
sleepiness, cardiovascular abnormalities and cognitive impairment impact greatly on daytime
functioning. The obese, hypertensives, elderly and postmenopausal women are reported to be at
increased risk for sleep apnea. The investigators published on the prevalence of sleep apnea
in several special populations: elderly subjects without sleep complaints and insomniac,
narcoleptic, hypertensive and obese patients. They established the prevalence of sleep apnea
in men based on the sleep laboratory evaluation of approximately 1,000 men randomly selected
from a randomly generated telephone sample of 4,364 men from the general population. Their
preliminary estimate of prevalence was that about 2.2 percent of the adult male population
have clinically diagnosable sleep apnea. Further, in the male sample, the age distribution
was not linearly related to age. Rather, it peaked at approximately age 55. Finally, the
major risk factors appeared to be obesity and snoring. The differences in the male/female
ratio in clinical and selected populations ranged from 10.0:1 to 1.9:1. One recent study
suggested that the prevalence of sleep apnea in women was about two-fold less than in men.
However, this study did not sample the general population and used only a restricted age
range (30 to 60 years) which did not allow the assessment of the influence of menopause.
Thus, the prevalence of sleep apnea in women in the general population remained largely
undetermined.
DESIGN NARRATIVE:
In order to establish the prevalence in women with reasonable precision, the prevalence study
employed a two-stage sample modified from the prevalence study in men in the following two
ways: an expanded telephone sample (N=12,219 women) selected randomly from the general
population was evaluated, for clinically relevant risk factors for sleep apnea; and 2) a
second sample (N=1,000) selected randomly from the first sample based on higher risk for
sleep apnea (including the additional risk factor of menopause) was evaluated in the sleep
laboratory to determine the presence of sleep apnea. This strategy yielded an adequate power
in order to establish the prevalence of sleep apnea requiring treatment and sleep disordered
breathing in women in the general population as well as result in a large enough sample to
establish the association between risk factors and sleep apnea in women. In order to perform
gender analyses, the study compared previously published data from a total of 4,364 men
interviewed in an expanded telephone sample and 741men evaluated in the sleep laboratory.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05563701 -
Evaluation of the LVivo Image Quality Scoring (IQS)
|
||
Completed |
NCT04908397 -
Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension
|
Phase 1 | |
Terminated |
NCT03309358 -
A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis
|
Phase 1 | |
Completed |
NCT03682354 -
ESPB Versus INB With PCIA in Video-assisted Thoracic Surgery
|
N/A | |
Enrolling by invitation |
NCT03683186 -
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
|
Phase 3 | |
Completed |
NCT03626519 -
Effects of Menthol on Dyspnoea in COPD Patients
|
N/A | |
Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Completed |
NCT02926768 -
Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT01443845 -
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)
|
Phase 4 | |
Terminated |
NCT00233207 -
IC14 Antibodies to Treat Individuals With Acute Lung Injury
|
Phase 2 | |
Completed |
NCT00269256 -
Stress, Environment, and Genetics in Urban Children With Asthma
|
N/A | |
Completed |
NCT00281216 -
Innate and Adaptive Immunity in Individuals Experiencing Chronic Obstructive Pulmonary Disease Exacerbations
|
N/A | |
Recruiting |
NCT00129350 -
Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation
|
Phase 1 | |
Active, not recruiting |
NCT00115297 -
Montelukast for Early Life Wheezing
|
Phase 2/Phase 3 | |
Completed |
NCT00094276 -
Intervention for Improving Asthma Care for Minority Children in Head Start
|
N/A | |
Completed |
NCT00091767 -
Genetic Studies in Difficult to Treat Asthma: TENOR
|
N/A | |
Completed |
NCT00089752 -
Continuous Positive Airway Pressure to Improve Milder Obstructive Sleep Apnea
|
N/A | |
Completed |
NCT00083798 -
Family Linkage Study of Obstructive Sleep Apnea (OSA) in Iceland
|
N/A | |
Completed |
NCT00233168 -
Effectiveness of Public Health Model of Latent Tuberculosis Infection Control for High-Risk Adolescents
|
N/A |